ny times

http://www.nytimes.com/2009/03/10/business/10drug.html?_r=1&th&emc=th

Read this the plot thickens.Merck to Buy Schering-Plough for $41.1 Billion

There is at least one big question that hangs over the proposed merger: What happens with Remicade, a rheumatoid arthritis drug that represented $2.1 billion in sales for Schering last year.

Schering markets Remicade outside the United States in an agreement with Johnson & Johnson, which sells the drug in this country. Under a termination clause in that agreement, the rights to Remicade and another drug under development could revert to Johnson & Johnson if control or ownership of Schering changes.

The offer is cats pis.Typical PEPTECH STUFF UP THE SHAREHOLDERS